Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy

Journal of Cardiovascular Magnetic Resonance

Volumn 16, Issue 1, 2014, Pages

  Mikami, Yoko ^a   Kolman, Louis ^a   Joncas, Sebastien X ^a   Stirrat, John ^b   Scholl, David ^b   Rajchl, Martin ^b   Lydell, Carmen P ^a   Weeks, Sarah G ^a   Howarth, Andrew G ^a   White, James A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Cardiovascular magnetic resonance; Hypertrophic cardiomyopathy; Late gadolinium enhancement

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; GADOBUTROL; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; AUTOMATION; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IMAGE QUALITY; LATE GADOLINIUM ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SIGNAL THRESHOLD VERSUS REFERENCE MEAN; AGED; CARDIOMYOPATHY, HYPERTROPHIC; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; EVALUATION STUDY; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; REGISTER;

ADULT; AGED; AUTOMATION; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; REGISTRIES; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84907533526     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/s12968-014-0085-x     Document Type: Article

References (29)

1. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. JC Moon, E Reed, MN Sheppard, AG Elkington, SY Ho, M Burke, M Petrou, DJ Pennell, J Am Coll Cardiol 2004 43 2260 2264 10.1016/j.jacc.2004.03.035 15193690
2. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. DH Kwon, NG Smedira, ER Rodriguez, C Tan, R Setser, M Thamilarasan, BW Lytle, HM Lever, MY Desai, J Am Coll Cardiol 2009 54 242 249 10.1016/j.jacc.2009.04.026 19589437
3. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. T Papavassiliu, P Schnabel, M Schröder, M Borggrefe, Eur Heart J 2005 26 2395 10.1093/eurheartj/ehi518 16263729
4. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. O Bruder, A Wagner, CJ Jensen, S Schneider, P Ong, E-M Kispert, K Nassenstein, T Schlosser, GV Sabin, U Sechtem, H Mahrholdt, J Am Coll Cardiol 2010 56 875 887 10.1016/j.jacc.2010.05.007 20667520
5. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. AS Adabag, BJ Maron, E Appelbaum, CJ Harrigan, JL Buros, CM Gibson, JR Lesser, CA Hanna, JE Udelson, WJ Manning, MS Maron, J Am Coll Cardiol 2008 51 1369 1374 10.1016/j.jacc.2007.11.071 18387438
6. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. CJ Harrigan, DC Peters, CM Gibson, BJ Maron, WJ Manning, MS Maron, E Appelbaum, Radiology 2011 258 128 133 10.1148/radiol.10090526 21045187
7. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. LC Amado, BL Gerber, SN Gupta, DW Rettmann, G Szarf, R Schock, K Nasir, DL Kraitchman, JA Lima, J Am Coll Cardiol 2004 44 2383 10.1016/j.jacc.2004.09.020 15607402
8. Auto-threshold quantification of late gadolinium enhancement in patients with acute heart disease. E Vermes, H Childs, I Carbone, P Barckow, MG Friedrich, J Magn Reson Imaging 2013 37 382 390 10.1002/jmri.23814 23011840
9. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. AS Flett, J Hasleton, C Cook, D Hausenloy, G Quarta, C Ariti, V Muthurangu, JC Moon, JACC Cardiovasc Imaging 2011 4 150 156 10.1016/j.jcmg.2010.11.015 21329899
10. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. M Spiewak, LA Malek, J Misko, L Chojnowska, B Milosz, M Klopotowski, J Petryka, M Dabrowski, C Kepka, W Ruzyllo, Eur J Radiol 2010 74 149 e153 10.1016/j.ejrad.2009.05.035 19523780
11. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. BJ Gersh, BJ Maron, RO Bonow, JA Dearani, MA Fifer, MS Link, SS Naidu, RA Nishimura, SR Ommen, H Rakowski, CE Seidman, JA Towbin, JE Udelson, CW Yancy, J Am Coll Cardiol 2011 58 212 e260 10.1016/j.jacc.2011.06.011 22075469
12. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. MS Maron, E Appelbaum, CJ Harrigan, J Buros, CM Gibson, C Hanna, JR Lesser, JE Udelson, WJ Manning, BJ Maron, Circ Heart Fail 2008 1 184 191 10.1161/CIRCHEARTFAILURE.108.768119 19808288
13. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. R Rubinshtein, JF Glockner, SR Ommen, PA Araoz, MJ Ackerman, P Sorajja, JM Bos, AJ Tajik, US Valeti, RA Nishimura, BJ Gersh, Circ Heart Fail 2010 3 51 58 10.1161/CIRCHEARTFAILURE.109.854026 19850699
14. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. R O'Hanlon, A Grasso, M Roughton, JC Moon, S Clark, R Wage, J Webb, M Kulkarni, D Dawson, L Sulaibeekh, B Chandrasekaran, C Bucciarelli-Ducci, F Pasquale, MR Cowie, WJ McKenna, MN Sheppard, PM Elliott, DJ Pennell, SK Prasad, J Am Coll Cardiol 2010 56 867 874 10.1016/j.jacc.2010.05.010 20688032
15. Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, Das B, Khwaja J, Alpendurada FD, Wage R, Roughton M, McKenna WJ, Moon JC, Varnava A, Shakespeare C, Cowie MR, Cook SA, Elliott P, O'Hanlon R, Pennell DJ, Prasad SK. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart. 2014; Published Online First: Jun 24. doi:10.1136/heartjnl-2013-305471.
16. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. RH Chan, BJ Maron, I Olivotto, MJ Pencina, GE Assenza, T Haas, JR Lesser, C Gruner, AM Crean, H Rakowski, JE Udelson, E Rowin, M Lombardi, F Cecchi, B Tomberli, P Spirito, F Formisano, E Biagini, C Rapezzi, CN De Cecco, C Autore, EF Cook, SN Hong, CM Gibson, WJ Manning, E Appelbaum, MS Maron, Circulation 2014 130 484 495 10.1161/CIRCULATIONAHA.113.007094 25092278
17. Histopathological types of cardiac fibrosis in myocardial disease. KR Anderson, MG Sutton, JT Lie, J Pathol 1979 128 79 85 10.1002/path.1711280205 572867
18. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. P Melacini, C Basso, A Angelini, C Calore, F Bobbo, B Tokajuk, N Bellini, G Smaniotto, M Zucchetto, S Iliceto, G Thiene, BJ Maron, Eur Heart J 2010 31 2111 2123 10.1093/eurheartj/ehq136 20513729
19. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. CY Ho, SA Abbasi, TG Neilan, RV Shah, Y Chen, B Heydari, AL Cirino, NK Lakdawala, EJ Orav, A González, B López, J Díez, M Jerosch-Herold, RY Kwong, Circ Cardiovasc Imaging 2013 6 415 422 10.1161/CIRCIMAGING.112.000333 23549607
20. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. S Dass, JJ Suttie, SK Piechnik, VM Ferreira, CJ Holloway, R Banerjee, M Mahmod, L Cochlin, TD Karamitsos, MD Robson, H Watkins, S Neubauer, Circ Cardiovasc Imaging 2012 5 726 733 10.1161/CIRCIMAGING.112.976738 23071146
21. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. S Bull, GJI Majno, SK White, SK Piechnik, AS Flett, VM Ferreira, M Loudon, JM Francis, TD Karamitsos, BD Prendergast, MD Robson, S Neubauer, JC Moon, SG Myerson, Heart 2013 99 932 937 10.1136/heartjnl-2012-303052 23349348
22. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. P Kellman, JR Wilson, H Xue, WP Bandettini, SM Shanbhag, KM Druey, M Ugander, AE Arai, J Cardiovasc Magn Reson 2012 14 64 10.1186/1532-429X-14-64 22967246
23. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. CY Ho, B López, OR Coelho-Filho, NK Lakdawala, AL Cirino, P Jarolim, R Kwong, A González, SD Colan, JG Seidman, J Díez, CE Seidman, N Engl J Med 2010 363 552 563 10.1056/NEJMoa1002659 20818890
24. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. G Todiere, GD Aquaro, P Piaggi, F Formisano, A Barison, PG Masci, E Strata, L Bacigalupo, M Marzilli, A Pingitore, M Lombardi, J Am Coll Cardiol 2012 60 922 929 10.1016/j.jacc.2012.03.076 22935464
25. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. AT Yan, AJ Shayne, KA Brown, SN Gupta, CW Chan, TM Luu, MF Di Carli, HG Reynolds, WG Stevenson, RY Kwong, Circulation 2006 114 32 10.1161/CIRCULATIONAHA.106.613414 16801462
26. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. A Schmidt, CF Azevedo, A Cheng, SN Gupta, DA Bluemke, TK Foo, G Gerstenblith, RG Weiss, E Marban, GF Tomaselli, JA Lima, KC Wu, Circulation 2007 115 2006 10.1161/CIRCULATIONAHA.106.653568 17389270
27. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. SD Roes, CJ Borleffs, RJ Van der Geest, JJ Westenberg, NA Marsan, TA Kaandorp, JH Reiber, K Zeppenfeld, HJ Lamb, A De Roos, MJ Schalij, JJ Bax, Circ Cardiovasc Imaging 2009 2 183 10.1161/CIRCIMAGING.108.826529 19808591
28. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. E Appelbaum, BJ Maron, S Adabag, TH Hauser, JR Lesser, TS Haas, AB Riley, CJ Harrigan, FN Delling, JE Udelson, CM Gibson, WJ Manning, MS Maron, Circ Cardiovasc Imaging 2012 5 78 85 10.1161/CIRCIMAGING.111.963819 22135401
29. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. G Moravsky, E Ofek, H Rakowski, J Butany, L Williams, A Ralph-Edwards, BJ Wintersperger, A Crean, JACC Cardiovasc Imaging 2013 6 587 596 10.1016/j.jcmg.2012.09.018 23582356